Published in Nat Biotechnol on June 01, 2014
A Landscape of Pharmacogenomic Interactions in Cancer. Cell (2016) 2.07
Inferring causal molecular networks: empirical assessment through a community-based effort. Nat Methods (2016) 1.04
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene (2014) 1.00
Harnessing Big Data for Systems Pharmacology. Annu Rev Pharmacol Toxicol (2016) 0.99
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol (2016) 0.98
The proteomic landscape of triple-negative breast cancer. Cell Rep (2015) 0.94
Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Mol Cancer Res (2015) 0.93
DREAMing of benchmarks. Nat Biotechnol (2015) 0.89
Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biol (2016) 0.88
Prediction of human population responses to toxic compounds by a collaborative competition. Nat Biotechnol (2015) 0.88
Predicting Anticancer Drug Responses Using a Dual-Layer Integrated Cell Line-Drug Network Model. PLoS Comput Biol (2015) 0.87
Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel. Bioinformatics (2015) 0.87
In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med (2016) 0.85
Data- and knowledge-based modeling of gene regulatory networks: an update. EXCLI J (2015) 0.85
Cancer: A most exceptional response. Nature (2015) 0.84
Prediction of the potency of mammalian cyclooxygenase inhibitors with ensemble proteochemometric modeling. J Cheminform (2015) 0.83
Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection. BMC Cancer (2015) 0.82
Drug Response Prediction as a Link Prediction Problem. Sci Rep (2017) 0.81
Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma. BMC Bioinformatics (2016) 0.81
Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine. Yonsei Med J (2015) 0.79
Analysis of individual protein regions provides novel insights on cancer pharmacogenomics. PLoS Comput Biol (2015) 0.79
Hierarchical Feature Selection Incorporating Known and Novel Biological Information: Identifying Genomic Features Related to Prostate Cancer Recurrence. J Am Stat Assoc (2017) 0.78
Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib. PLoS One (2015) 0.78
A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. PLoS Comput Biol (2016) 0.78
Providing data science support for systems pharmacology and its implications to drug discovery. Expert Opin Drug Discov (2016) 0.78
Breast cancer tumorigenicity is dependent on high expression levels of NAF-1 and the lability of its Fe-S clusters. Proc Natl Acad Sci U S A (2016) 0.78
Integrative modelling of tumour DNA methylation quantifies the contribution of metabolism. Nat Commun (2016) 0.77
Multitask learning improves prediction of cancer drug sensitivity. Sci Rep (2016) 0.77
Cellular heterogeneity mediates inherent sensitivity-specificity tradeoff in cancer targeting by synthetic circuits. Proc Natl Acad Sci U S A (2016) 0.77
Context Sensitive Modeling of Cancer Drug Sensitivity. PLoS One (2015) 0.77
DREAMTools: a Python package for scoring collaborative challenges. F1000Res (2015) 0.77
A systems approach to drug discovery in Alzheimer's disease. Neurotherapeutics (2015) 0.77
A Copula Based Approach for Design of Multivariate Random Forests for Drug Sensitivity Prediction. PLoS One (2015) 0.77
Integrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell Lines. PLoS One (2016) 0.77
Inferences of drug responses in cancer cells from cancer genomic features and compound chemical and therapeutic properties. Sci Rep (2016) 0.76
Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun (2016) 0.76
A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. Front Genet (2015) 0.75
Context-specific functional module based drug efficacy prediction. BMC Bioinformatics (2016) 0.75
Mining the Breast Cancer Proteome for Predictors of Drug Sensitivity. J Proteomics Bioinform (2015) 0.75
Combination therapy design for maximizing sensitivity and minimizing toxicity. BMC Bioinformatics (2017) 0.75
TarNet: An Evidence-Based Database for Natural Medicine Research. PLoS One (2016) 0.75
Early spatiotemporal-specific changes in intermediate signals are predictive of cytotoxic sensitivity to TNFα and co-treatments. Sci Rep (2017) 0.75
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. Oncotarget (2016) 0.75
CloudForest: A Scalable and Efficient Random Forest Implementation for Biological Data. PLoS One (2015) 0.75
The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology. Oncotarget (2016) 0.75
BIGCHEM: Challenges and Opportunities for Big Data Analysis in Chemistry. Mol Inform (2016) 0.75
An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine. Sci Rep (2016) 0.75
High-dimensional omics data analysis using a variable screening protocol with prior knowledge integration (SKI). BMC Syst Biol (2016) 0.75
Computational dynamic approaches for temporal omics data with applications to systems medicine. BioData Min (2017) 0.75
Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbations. Oncotarget (2016) 0.75
Pareto Optimization Identifies Diverse Set of Phosphorylation Signatures Predicting Response to Treatment with Dasatinib. PLoS One (2015) 0.75
Cheminformatics Research at the Unilever Centre for Molecular Science Informatics Cambridge. Mol Inform (2015) 0.75
HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B. PLoS Comput Biol (2016) 0.75
Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). Oncotarget (2016) 0.75
ApoCanD: Database of human apoptotic proteins in the context of cancer. Sci Rep (2016) 0.75
Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res (2016) 0.75
A New View of Pathway-Driven Drug Resistance in Tumor Proliferation. Trends Pharmacol Sci (2017) 0.75
Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs. Nat Commun (2017) 0.75
Integrative systems and synthetic biology of cell-matrix adhesion sites. Cell Adh Migr (2016) 0.75
Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance. Genome Biol (2017) 0.75
Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. Genome Res (2017) 0.75
Metabolic network segmentation: A probabilistic graphical modeling approach to identify the sites and sequential order of metabolic regulation from non-targeted metabolomics data. PLoS Comput Biol (2017) 0.75
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. NPJ Syst Biol Appl (2017) 0.75
Integrative network and transcriptomics-based approach predicts genotype- specific drug combinations for melanoma. AMIA Jt Summits Transl Sci Proc (2017) 0.75
Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization. BMC Cancer (2017) 0.75
Functional proteomic characterization of cancer cell lines. Oncoscience (2017) 0.75
A link prediction approach to cancer drug sensitivity prediction. BMC Syst Biol (2017) 0.75
Predicting ligand-dependent tumors from multi-dimensional signaling features. NPJ Syst Biol Appl (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Hallmarks of cancer: the next generation. Cell (2011) 140.01
KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res (2000) 117.00
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw (2010) 38.65
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
International network of cancer genome projects. Nature (2010) 20.35
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics (2007) 14.25
The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (1991) 9.39
Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (2010) 8.44
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Molecular signatures database (MSigDB) 3.0. Bioinformatics (2011) 8.08
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Wisdom of crowds for robust gene network inference. Nat Methods (2012) 6.91
Alternative expression analysis by RNA sequencing. Nat Methods (2010) 5.02
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res (2012) 4.34
Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet (2011) 3.60
A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics (2009) 2.90
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12
Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol (2013) 1.75
Simultaneous identification of multiple driver pathways in cancer. PLoS Comput Biol (2013) 1.71
Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS One (2013) 1.50
Collections of simultaneously altered genes as biomarkers of cancer cell drug response. Cancer Res (2013) 1.23
A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med (2009) 1.22
Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene (2011) 1.19
Seeking the wisdom of crowds through challenge-based competitions in biomedical research. Clin Pharmacol Ther (2013) 1.18
A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol (2014) 1.24
Probe Region Expression Estimation for RNA-Seq Data for Improved Microarray Comparability. PLoS One (2015) 0.81
Inference of RNA polymerase II transcription dynamics from chromatin immunoprecipitation time course data. PLoS Comput Biol (2014) 0.80
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. Blood Cancer J (2015) 0.78
A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines. Cell Syst (2017) 0.75
Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors. PLoS Comput Biol (2017) 0.75